Andusomeran is an mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus, including the XBB.1.5 subvariant. It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.
- Mechanism
- Curator reviewed · 4 references
Moderna's COVID-19 mRNA vaccine is composed of synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2. The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell. Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to protection against SARS-CoV-2.
Andusomeran is a COVID-19 mRNA vaccine that encodes for the pre-fusion stabilized S glycoprotein of the SARS-CoV-2 Omicron subvariant XBB.1.5 (containing mutations K982P and V983P) which is intended to elicit protection against this variant.
- Primary indication
- Andusomeran is indicated for the prevention of COVID-19 caused by SARS-CoV-2.Curator reviewed · 3 structured indications
- First approval
- Canada, 2023 · United States, 2023
- Also known as
- Moderna COVID-19 Vaccine 2023-2024
Resolves to
What you can answer from here — as of October 16, 2025
Which other approved drugs treat the same conditions as Andusomeran, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account